Breaking News, Financial News

Financial Report: Roche

Roche

FY Revenues: $34.5 billion (+17%)*

FY Earnings: $7.3 billion (+34%)*

Comments: Pharmaceutical sales were up 21% to $27.3 billion driven primarily by key oncology products: MabThera/Rituxan, Herceptin, Avastin, and Xeloda; the flu medicine Tamiflu, Genentech’s ophthalmology drug Lucentis, and the osteoporosis medicine Bonviva/Boniva. The company received marketing approvals for Avastin in lung cancer, Herceptin in early-stage breast cancer and MabThera/Rituxan in rheumatoid arthritis. R&D spending was $5.4 billion for the year, up 16%.

* includes revenues from Genentech and Chugai subsidiaries

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters